March 2018

New Product - Cabometyx

Cabometyx (cabozantinib) inhibits multiple receptor tyrosine kinases implicated in tumour growth and angiogenesis, and metastatic progression of cancer. Cabozantinib is an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. In addition, cabozantinib inhibits other tyrosine kinases including AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT3 and TIE-2. Cabometyx is indicated for the treatment of advanced renal cell carcinoma in adults following prior treatment with VEGF targeted therapy. Cabometyx 20 mg, 40 mg and 60 mg tablets are available in packs of 30.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au